ProfileGDS5678 / 1452716_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 83% 88% 93% 90% 85% 92% 95% 95% 95% 83% 91% 86% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.281591
GSM967853U87-EV human glioblastoma xenograft - Control 26.1865483
GSM967854U87-EV human glioblastoma xenograft - Control 36.8332988
GSM967855U87-EV human glioblastoma xenograft - Control 48.007693
GSM967856U87-EV human glioblastoma xenograft - Control 57.3055590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1770485
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4663192
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.3920295
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.4088995
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.4025195
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0363783
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5148691
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4595986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.751888